Lexicon Pharma (LXRX) Misses Q1 EPS by 4c
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $2.04 --0%
Revenue Growth %: -78.9%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
VFS, More
Revenue Growth %: -78.9%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
VFS, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q1 EPS of ($0.34), $0.04 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $12.5 million versus the consensus estimate of $11.11 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald’s said to plan value strategy overhaul to revive US sales growth
- Canaccord Reiterates Buy Rating on HubSpot Inc (HUBS)
- UBS Upgrades Kyocera (6971:JP) (KYOCY) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
